Wenwen Jiang

A seasoned professional with over eight years of experience at the intersection of corporate law, mergers and acquisitions, and scientific innovation, Wenwen is a distinguished strategist and leader. She combines a deep understanding of complex legal and regulatory frameworks with a robust background in pharmaceutical science and a forward-thinking approach to technology governance. Her career is marked by a unique ability to navigate high-stakes environments, from multi-billion-dollar M&A transactions to pioneering work in AI risk management.

As a strategic advisor, Wenwen has been instrumental in some of the most prominent transactions in U.S. sports and corporate law. She helped lead the legal, public relations, and deal strategy for Steve Cohen’s landmark $2.4 billion acquisition of the New York Mets—the largest in U.S. sports history. Her expertise extends to litigation and risk management, where she was involved in a high-profile RICO case against Major League Baseball and led a class-action lawsuit against a major financing firm and over 20 auto dealers. She has also provided critical litigation support for defamation and malpractice lawsuits involving prominent public figures, including Lenny Dykstra. Furthermore, her work as an M&A Advisor at MergersCorp demonstrates her total command of the transaction lifecycle, from rigorous due diligence and negotiation to post-closing integration and regulatory compliance.

Complementing her legal career is a solid foundation in science and healthcare, cultivated during her tenure as a research analyst and project manager at Pfizer. In this role, she supported documentation for intricate due diligence processes and complex post-acquisition product transfers. During the COVID-19 pandemic, her expertise was vital in supporting the White House’s national response efforts and securing Emergency Use Authorization (EUA) from the FDA for critical COVID-19 test kits. Her healthcare portfolio also includes key contributions to a major drug licensing agreement for Amgen, alongside extensive command over FDA and SEC regulatory filings.

Recognizing the evolving challenges of an increasingly technology-driven world, Wenwen created RADAR, an innovative AI governance scoring model that systematically flags regulatory risk. This proprietary tool assesses a firm’s AI readiness and has been successfully applied in M&A due diligence, policy evaluations, and compliance audits, reducing due diligence time by up to 40%. As the Chief Governance Strategist at RADAR Governance, she has positioned this solution as a vital bridge connecting corporate strategy, public policy, and emerging regulation.

Through her rare combination of legal precision, business acumen, and systems thinking, Wenwen consistently drives exceptional outcomes in dynamic, heavily regulated industries.